It is not surprising that a new study on the relationship between income and longevity in the United States concludes that life expectancy increased with income. However, the study did shed light on the variabilities in the income-longevity relationship.
It is not surprising that a new study on the relationship between income and longevity in the United States concludes that life expectancy increased with income. However, the study did shed light on the variabilities in the income-longevity relationship.
The study used income data for the US population that were obtained from 1.4 billion deidentified tax records of individuals ages 40 to 76 years between 1999 and 2014. Social Security Administration death records provided mortality data. These data were used to estimate race- and ethnicity-adjusted life expectancy at 40 years of age by household income percentile, sex, and geographic area, and to analyze factors associated with differences in life expectancy. The main findings were as follows:
The strongest pattern in the data was that low-income individuals tend to live longest and have more healthy behaviors in cities with highly educated populations, high incomes, and high levels of government expenditures such as New York City and San Francisco. In these cities, life expectancy for people in the bottom 5% of income distribution was approximately 80 years; in contrast, in cities such as Detroit, Michigan, the expected age at death for those in the bottom 5% was approximately 75 years.
Low-income individuals living in cities with highly educated populations and high incomes also had the largest gains in life expectancy during the 2000s, the authors said.
The researchers conclude that reducing gaps in longevity may require local policy responses, and that health professionals make targeted efforts to improve health among low-income populations with policy interventions focusing on changing health behaviors among low-income people. Tax policies and other local public policies may play a role in inducing such changes, they advise.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More